CLINICAL_TRIALS trial_result · 2021-07-22

Clinical Trial Update: Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis [Phase 1, Phase 2]

A completed Phase 1/2 clinical trial evaluating RVL-1201 for acquired blepharoptosis, with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: RVL Pharmaceuticals, Inc. | Conditions: Blepharoptosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-07-22